Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. - Test2 - elhamkhani - TriplyDB

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

http://www.wikidata.org/entity/Q29619254

about

HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response Drug-eluting fibers for HIV-1 inhibition and contraception Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1 Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages A lectin isolated from bananas is a potent inhibitor of HIV replication The IFITM proteins inhibit HIV-1 infection Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism Characterizing the anti-HIV activity of papuamide A Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation Potent D-peptide inhibitors of HIV-1 entry An RNA targeted to the HIV-1 LTR promoter modulates indiscriminate off-target gene activation COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells Efficient trapping of HIV-1 envelope protein by hetero-oligomerization with an N-helix chimera.Current perspectives on HIV-1 antiretroviral drug resistance Virological features associated with the development of broadly neutralizing antibodies to HIV-1 Fusion of mature HIV-1 particles leads to complete release of a gag-GFP-based content marker and raises the intraviral pH Time-Resolved Imaging of Single HIV-1 Uncoating In Vitro and in Living Cells Renal epithelial cells produce and spread HIV-1 via T-cell contact Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations.Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells Structural Insights into HIV-1 Vif-APOBEC3F Interaction P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions Visualization of Content Release from Cell Surface-Attached Single HIV-1 Particles Carrying an Extra-Viral Fluorescent pH-Sensor Vaginal challenge with an SIV-based dual reporter system reveals that infection can occur throughout the upper and lower female reproductive tract Synchronized retrovirus fusion in cells expressing alternative receptor isoforms releases the viral core into distinct sub-cellular compartments Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus FGI-104: a broad-spectrum small molecule inhibitor of viral infection Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env Structural and biological mimicry of protein surface recognition by / -peptide foldamers Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide

P2860

Q21090490-D05C8421-938E-44B5-9CD2-48D1989F9748 Q21133885-EDE4959B-1730-47C9-A8E0-C07CC2EC89B4 Q21133918-032265A3-6817-4113-BFDA-36BE9EFF882D Q22252313-8CA692B2-3F62-4C4A-9005-003BAFBEBC5B Q24294385-1B1B5935-7BC6-48F8-9E11-0642A1129787 Q24310242-7BCB8D14-F4F4-4A58-AB69-098A4A88BA2A Q24336824-AF131CBE-3792-42FC-970B-CCD20BD823C9 Q24596322-9984B192-A876-4EA7-ADF7-27C5788EBB24 Q24598653-C6C3EF98-1A22-45EB-A2C2-F2BDEFACA1DB Q24606095-3C3D48C2-8E16-4422-B71E-CAA824A8EBBA Q24611223-B614DE24-0A34-4B46-93AE-704AE7ED7BD2 Q24629155-E3BA902C-1E77-4BA1-8F9A-A66043C805F2 Q24629626-AF847D99-F974-4DBD-9598-29420AAEAAF2 Q24644811-63FB8D7A-E129-4749-8D2E-0473F448DADA Q24645399-B05746F1-E7A5-4D84-95A9-06F0B8861224 Q24651042-6E562791-9BF6-4891-8C3A-1E50F5599D32 Q24672209-31C1DEE3-40C0-4F80-A8BD-B4D16D0B21D6 Q24675493-D46F842F-1305-407A-AEFC-F440518C6DA0 Q24685792-B25D3002-CB79-4DC1-820A-CB76A56FA8C8 Q24806175-F38E8C0C-8657-4193-9504-11860AC29169 Q24811678-D4870CC5-6447-40C7-9BC0-004FC9CD70D8 Q26852626-EF44102C-03BF-4E68-AD68-D98EBA941A39 Q27025177-861C3E2F-4507-41B4-8D32-64E5210428FD Q27309923-B5427B7F-FC14-4438-9069-1E43C0E3BAD5 Q27313409-61EC2CB9-2CD9-44B2-87A8-1A33171D22B0 Q27313558-FA5BA8C5-6590-4422-A8B5-2F131A248AD6 Q27315206-1E089973-F90F-49B8-A542-4467F8C76A11 Q27320687-BE540AC2-DDE0-4A27-87D4-D8AF6091D605 Q27321018-33F4C747-4469-4106-ADA7-539D208E68E5 Q27321418-DA0256A6-94CD-4C17-A6B0-D42908F301F3 Q27322507-0A8FC4D3-836D-4066-9B7C-6573C2324CEC Q27323310-7B434301-CF18-4466-B6A3-2E71BC3F9840 Q27345572-EE1F1BBF-C511-4E61-BFA9-DCD1C82EB6A5 Q27485703-1291B789-AA20-4CD1-8151-928BFDA2471E Q27490384-F28E41BB-610D-473A-862C-9E21AD0C24C2 Q27644383-5458A5FB-F682-4ABB-9623-44DFBA12C2C4 Q27657158-63849366-14D6-41F0-8F55-4DCE27B96AB5 Q27657257-670D5671-CA20-41D5-8068-D6E2B6B32769 Q27661588-0D867728-0A70-41F0-B2DF-1B4E09FE9133 Q27666404-8E7CF46A-0041-488E-AE69-5ED59DB811E5

P2860

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

http://www.wikidata.org/entity/Q29619254

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Emergence of resistant human i ...... inhibitor (T-20) monotherapy.

@ast

Emergence of resistant human i ...... inhibitor (T-20) monotherapy.

@en

type

label

Emergence of resistant human i ...... inhibitor (T-20) monotherapy.

@ast

Emergence of resistant human i ...... inhibitor (T-20) monotherapy.

@en

prefLabel

Emergence of resistant human i ...... inhibitor (T-20) monotherapy.

@ast

Emergence of resistant human i ...... inhibitor (T-20) monotherapy.

@en

P1433

Q29619254-EBB67A59-DDE1-4BBE-B748-AB54C3C2D885

P1476

Q29619254-19348FF1-03DE-426B-A467-0106104BF580

P2093

Q29619254-1348C081-B796-4C16-9410-2D95BEFFB680

Q29619254-13D3827B-D85E-439F-A07A-5B4EC3D56946

Q29619254-29811316-BBB3-48C2-8453-7D56928B79B2

Q29619254-5D7F96FA-6225-4D0A-9F53-2B7F16352915

Q29619254-6DA6BA9F-C982-4401-90FB-2DF683BB1F77

Q29619254-7C668CBC-C827-40B3-99FC-6C29B7372FF8

Q29619254-8CF33905-F2A4-410F-8D5D-AF5980DCF673

Q29619254-A788899C-F00C-4A85-9DCA-6B590DD0130E

P2860

Q29619254-12986F75-97C2-4527-9C54-275A97BF92BF

Q29619254-15D5CBBB-B74F-40CC-8EC7-D0004827D8DB

Q29619254-1D5C0CC2-BFD9-4107-B81B-5DAD8A15AC89

Q29619254-2450020A-90ED-4810-8486-9F4C186171FD

Q29619254-27174266-DB90-4013-B4FE-8C4EAD5609D2

Q29619254-376755BE-5F9F-4561-90A3-1BFCDDD6A55A

Q29619254-50173418-1E43-4D72-AACA-8AA627991E02

Q29619254-556FFFCE-C26D-41C5-92A2-7798B307BEFA

Q29619254-61D392D4-9235-41DE-BEBF-475744467D5A

Q29619254-63CC05AC-3430-4E21-93AC-D5E858644EE0

P304

Q29619254-A025BA2A-69AD-45AA-9ED6-3AA7D4E9CC46

P31

Q29619254-8ADBAFED-FEFE-4D81-85FC-9963B1D70D83

P3181

Q29619254-9B248128-CCFC-4812-A8DC-79E9F734B4F0

P356

Q29619254-82EFEECC-691C-468C-BD02-3527663700AB

P407

Q29619254-5C249877-36DA-406F-B5B9-48EB325B1541

P433

Q29619254-D310178B-8C5A-4AFC-909F-72D126FC98F3

P478

Q29619254-9A895472-52D2-4507-AFF8-F816F92F15F6

P50

Q29619254-170583C6-7946-4626-B94F-7DC326D3ACD9

Q29619254-F5B7D8A2-4510-4BB2-9699-ECA9923770DB

P577

Q29619254-6337E5D7-A1DC-4FAA-961D-EFC4283C86F9

P698

Q29619254-9B8B873F-F960-43FA-9DFE-4BD7AC18FDDD

P921

Q29619254-B447360C-8D84-428A-9071-705FEE5F8036

P932

Q29619254-0CCEEA55-0124-40E8-8C93-FB78411EDCA2

P3181

P356

AAC.46.6.1896-1905.2002

P1433

Antimicrobial Agents and Chemotherapy

P1476

Emergence of resistant human i ...... n inhibitor (T-20) monotherapy

@en

P2093

Hongmei Liu

http://www.w3.org/2001/XMLSchema#string

John C Kappes

http://www.w3.org/2001/XMLSchema#string

Julie M Decker

http://www.w3.org/2001/XMLSchema#string

Michael S Saag

http://www.w3.org/2001/XMLSchema#string

Ramin B Arani

http://www.w3.org/2001/XMLSchema#string

Xiaoyun Wu

http://www.w3.org/2001/XMLSchema#string

Xiping Wei

http://www.w3.org/2001/XMLSchema#string

Zee Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Core structure of gp41 from the HIV envelope glycoprotein

Atomic structure of the ectodomain from HIV-1 gp41

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

Viral dynamics in human immunodeficiency virus type 1 infection

P304

1896-1905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

190662

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.46.6.1896-1905.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

J. Michael Kilby

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12019106

http://www.w3.org/2001/XMLSchema#string

P921

membrane fusion involved in viral entry into host cell

P932

127242

http://www.w3.org/2001/XMLSchema#string